Nov 04, 2026 9:15am EST Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition
Oct 29, 2026 8:05am EDT Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results
Oct 19, 2026 8:05am EDT Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026
Aug 13, 2026 8:05am EDT Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
Jul 28, 2026 8:05am EDT Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
